ADMA Biologics markets three FDA-approved immune globulin products, with ASCENIV serving as its main growth driver. Read why ADMA stock is upgraded to strong buy.
Analysts Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this ar… [+771 chars]
